China Shineway Pharmaceutical Group 과거 수익 실적
과거 기준 확인 5/6
China Shineway Pharmaceutical Group은 연평균 20.8%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 증가했으며, 연간 5.7%였습니다. 매출은 연평균 13.4%의 비율로 증가했습니다. China Shineway Pharmaceutical Group의 자기자본이익률은 15.1%이고 순이익률은 26.3%입니다.
주요 정보
20.8%
수익 성장률
21.6%
EPS 성장률
| Pharmaceuticals 산업 성장 | 5.6% |
| 매출 성장률 | 13.4% |
| 자기자본 수익률 | 15.1% |
| 순이익 | 26.3% |
| 최근 수익 업데이트 | 30 Jun 2024 |
최근 과거 실적 업데이트
Recent updates
China Shineway Pharmaceutical Group Limited's (HKG:2877) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Oct 18
If EPS Growth Is Important To You, China Shineway Pharmaceutical Group (HKG:2877) Presents An Opportunity
Jun 03Is China Shineway Pharmaceutical Group (HKG:2877) A Risky Investment?
May 13China Shineway Pharmaceutical Group (HKG:2877) Has Announced That It Will Be Increasing Its Dividend To CN¥0.461
Apr 26Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 41%?
Apr 17China Shineway Pharmaceutical Group (HKG:2877) Is Increasing Its Dividend To CN¥0.461
Mar 31China Shineway Pharmaceutical Group Limited's (HKG:2877) 26% Price Boost Is Out Of Tune With Earnings
Mar 14Does China Shineway Pharmaceutical Group (HKG:2877) Deserve A Spot On Your Watchlist?
Jan 29China Shineway Pharmaceutical Group (HKG:2877) Seems To Use Debt Rather Sparingly
Sep 28China Shineway Pharmaceutical Group (HKG:2877) Is Paying Out A Dividend Of CN¥0.118
Sep 01We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease
Aug 03Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 44%?
May 30We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease
Mar 07China Shineway Pharmaceutical Group's (HKG:2877) Dividend Will Be Reduced To CN¥0.125
Sep 01China Shineway Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 31China Shineway Pharmaceutical Group (HKG:2877) Has A Rock Solid Balance Sheet
Apr 07China Shineway Pharmaceutical Group's(HKG:2877) Share Price Is Down 55% Over The Past Three Years.
Mar 11Should You Buy China Shineway Pharmaceutical Group Limited (HKG:2877) For Its Dividend?
Feb 18
Should You Use China Shineway Pharmaceutical Group's (HKG:2877) Statutory Earnings To Analyse It?
Jan 31Is China Shineway Pharmaceutical Group Limited (HKG:2877) Trading At A 49% Discount?
Jan 13What Is The Ownership Structure Like For China Shineway Pharmaceutical Group Limited (HKG:2877)?
Dec 25We Think China Shineway Pharmaceutical Group (HKG:2877) Can Manage Its Debt With Ease
Dec 10Reflecting on China Shineway Pharmaceutical Group's (HKG:2877) Share Price Returns Over The Last Five Years
Nov 25수익 및 비용 분석
수익 및 비용 분석
China Shineway Pharmaceutical Group 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 30 Jun 24 | 4,205 | 1,105 | 2,111 | 107 |
| 31 Mar 24 | 4,361 | 1,037 | 2,212 | 109 |
| 31 Dec 23 | 4,517 | 970 | 2,314 | 110 |
| 30 Sep 23 | 4,525 | 926 | 2,318 | 124 |
| 30 Jun 23 | 4,534 | 883 | 2,323 | 137 |
| 31 Mar 23 | 4,242 | 803 | 2,215 | 127 |
| 31 Dec 22 | 3,951 | 723 | 2,107 | 117 |
| 30 Sep 22 | 3,718 | 651 | 2,004 | 117 |
| 30 Jun 22 | 3,485 | 579 | 1,902 | 116 |
| 31 Mar 22 | 3,354 | 568 | 1,832 | 115 |
| 31 Dec 21 | 3,224 | 557 | 1,763 | 113 |
| 30 Sep 21 | 3,122 | 453 | 1,676 | 109 |
| 30 Jun 21 | 3,020 | 350 | 1,590 | 105 |
| 31 Mar 21 | 2,838 | 322 | 1,528 | 102 |
| 31 Dec 20 | 2,656 | 295 | 1,466 | 100 |
| 30 Sep 20 | 2,592 | 382 | 1,425 | 88 |
| 30 Jun 20 | 2,528 | 469 | 1,384 | 77 |
| 31 Mar 20 | 2,617 | 486 | 1,393 | 90 |
| 31 Dec 19 | 2,706 | 503 | 1,402 | 103 |
| 30 Sep 19 | 2,670 | 520 | 1,367 | 102 |
| 30 Jun 19 | 2,633 | 537 | 1,332 | 100 |
| 31 Mar 19 | 2,602 | 521 | 1,293 | 114 |
| 31 Dec 18 | 2,570 | 506 | 1,254 | 128 |
| 30 Sep 18 | 2,492 | 516 | 1,174 | 136 |
| 30 Jun 18 | 2,413 | 526 | 1,095 | 144 |
| 31 Mar 18 | 2,166 | 489 | 929 | 120 |
| 31 Dec 17 | 1,920 | 452 | 763 | 97 |
| 30 Sep 17 | 1,897 | 474 | 708 | 81 |
| 30 Jun 17 | 1,873 | 496 | 653 | 66 |
| 31 Mar 17 | 1,933 | 542 | 651 | 70 |
| 31 Dec 16 | 1,993 | 589 | 648 | 74 |
| 30 Sep 16 | 1,935 | 569 | 659 | 79 |
| 30 Jun 16 | 1,877 | 549 | 669 | 84 |
| 31 Mar 16 | 1,966 | 603 | 673 | 76 |
| 31 Dec 15 | 2,055 | 658 | 678 | 69 |
| 30 Sep 15 | 2,147 | 672 | 691 | 73 |
| 30 Jun 15 | 2,239 | 685 | 705 | 78 |
| 31 Mar 15 | 2,234 | 695 | 701 | 79 |
| 31 Dec 14 | 2,229 | 705 | 697 | 80 |
| 30 Sep 14 | 2,228 | 704 | 697 | 79 |
| 30 Jun 14 | 2,227 | 703 | 698 | 78 |
| 31 Mar 14 | 2,207 | 693 | 699 | 81 |
| 31 Dec 13 | 2,187 | 684 | 701 | 83 |
양질의 수익: 2877 은 높은 수익을 보유하고 있습니다.
이익 마진 증가: 2877 의 현재 순이익 이익률 (26.3%) 작년보다 높습니다 (19.5%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: 2877 의 수익은 지난 5년 동안 매년 20.8% 씩 크게 증가했습니다.
성장 가속화: 지난 1년간 2877 의 수익 증가율( 25.1% )은 연간 평균( 20.8% 초과합니다. ).
수익 대 산업: 지난 1년간 2877 수익 증가율( 25.1% )은 Pharmaceuticals 업계 6.4% 초과했습니다.
자기자본 수익률
높은 ROE: 2877 의 자본 수익률( 15.1% )은 낮음으로 간주됩니다.